PMID- 35320057
OWN - NLM
STAT- MEDLINE
DCOM- 20220427
LR  - 20220531
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 20
IP  - 3
DP  - 2022 Mar
TI  - Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors.
PG  - 223-232
LID - 10.1080/14779072.2022.2057949 [doi]
AB  - INTRODUCTION: This paper intended to review the data regarding the multipotential 
      effects of the sodium-glucose cotransporter 2 (SGLT 2) inhibitors, their 
      cardiovascular effects, and their mechanism of action. AREAS COVERED: The SGLT2 
      inhibitors exert their beneficial antidiabetic and cardioprotective effects 
      through increased glucose excretion from the kidneys, blood pressure and weight 
      lowering, vasodilation and other potential beneficial effects. They have been 
      used for the treatment of patients with type 2 diabetes mellitus (T2DM) as well 
      as in patients with cardiovascular disease (CVD), coronary artery disease 
      (CAD),and heart failure with reduced ejection fraction (HFrEF) and heart failure 
      with preserved ejection fraction (HFpEF). To get a better understanding of their 
      mechanism of action for their multiple cardiovascular protective effects, a 
      Medline search of the English language literature was conducted between 2015 and 
      February 2022 and 46 pertinent papers were selected. EXPERT OPINION: The analysis 
      of data clearly demonstrated that the use of the SGLT2 inhibitors besides their 
      antidiabetic effects, provide additional protection against CVD, CAD, and HFrEF 
      and HFpEF, and death, but not stroke, in both diabetic and non-diabetic patients. 
      Therefore, they should be preferably used for the treatment of patients with T2DM 
      with preexisting CVD, CAD, and HFrEF and HFpEF.
FAU - Chrysant, Steven G
AU  - Chrysant SG
AD  - Department of Cardiology, University of Oklahoma Health Sciences Center, Oklahoma 
      City, USA.
FAU - Chrysant, George S
AU  - Chrysant GS
AD  - Department of Cardiology, INTEGRIS Baptist Medical Center, Oklahoma City, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220420
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - *Cardiovascular Diseases/drug therapy/prevention & control
MH  - *Coronary Artery Disease
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glucose
MH  - *Heart Failure
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors/pharmacology/therapeutic use
MH  - Stroke Volume
OTO - NOTNLM
OT  - SGLT2 inhibitors
OT  - cardiovascular disease
OT  - coronary artery disease
OT  - death
OT  - diabetes
OT  - heart failure
EDAT- 2022/03/24 06:00
MHDA- 2022/04/28 06:00
CRDT- 2022/03/23 17:14
PHST- 2022/03/24 06:00 [pubmed]
PHST- 2022/04/28 06:00 [medline]
PHST- 2022/03/23 17:14 [entrez]
AID - 10.1080/14779072.2022.2057949 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2022 Mar;20(3):223-232. doi: 
      10.1080/14779072.2022.2057949. Epub 2022 Apr 20.